# Gufic Biosciences (NSE: GUFICBIO) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/GUFICBIO · Pivot · prices to 21 Oct 2026

Gufic Biosciences (NSE: GUFICBIO) closed at ₹381.90 on 21 Oct 2026. With a market capitalisation of ₹4,051 Cr, it ranks 875th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.

At its last close the stock traded at 63.1× trailing earnings, against a return on equity of 11.6% in FY25. Over the past year the share price has risen 10.7%. Its 52-week range is ₹268.00 (9 Mar 2026) to ₹467.80 (7 Sep 2026); the last close is 18.4% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹252 Cr (+22.8% year on year) and net profit ₹22 Cr (+183.7%), on a consolidated basis. Promoters held 72.50% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹381.90 |
| Market cap | ₹4,051 Cr |
| P/E (trailing) | 63.1 |
| ROE | 11.6% (FY25) |
| ROCE | 15.2% (FY25) |
| Debt to equity | 0.52 |
| 52-week high | ₹467.80 (7 Sep 2026) |
| 52-week low | ₹268.00 (9 Mar 2026) |
| 1-year return | +10.7% |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q4 FY26 | ₹252 Cr | +22.8% | ₹22 Cr | +183.7% | ₹2.18 |
| Q3 FY26 | ₹231 Cr | +11.4% | ₹12 Cr | −35.7% | ₹1.24 |
| Q2 FY26 | ₹237 Cr | +16.1% | ₹17 Cr | −22.7% | ₹1.68 |
| Q1 FY26 | ₹224 Cr | +10.3% | ₹13 Cr | −37.3% | ₹1.30 |
| Q4 FY25 | ₹205 Cr | +5.1% | ₹8 Cr | −61.5% | ₹0.77 |
| Q3 FY25 | ₹208 Cr | +3.0% | ₹19 Cr | −13.3% | ₹1.93 |
| Q2 FY25 | ₹204 Cr | −5.0% | ₹22 Cr | −6.2% | ₹2.17 |
| Q1 FY25 | ₹203 Cr | +4.0% | ₹21 Cr | +1.2% | ₹2.08 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹820 Cr | ₹70 Cr |
| FY24 | ₹807 Cr | ₹86 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 72.50%
- Foreign institutions: 0.46%
- Domestic institutions: 3.68%
- Non-institutions: 23.36%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Jeena Sikho Lifecare](https://app.pivotnow.in/stock/JSLL) | ₹367.20 | ₹4,564 Cr | 20.7 | — |
| [Orchid Pharma](https://app.pivotnow.in/stock/ORCHPHARMA) | ₹891.00 | ₹4,519 Cr | 217.8 | — |
| [SMS Pharmaceuticals](https://app.pivotnow.in/stock/SMSPHARMA) | ₹432.55 | ₹4,051 Cr | 38.8 | — |
| [Gujarat Themis Biosyn](https://app.pivotnow.in/stock/GUJTHEM) | ₹358.50 | ₹3,906 Cr | 83.8 | — |
| [Aarti Drugs](https://app.pivotnow.in/stock/AARTIDRUGS) | ₹399.00 | ₹3,642 Cr | 18.7 | — |
| [Unichem Laboratories](https://app.pivotnow.in/stock/UNICHEMLAB) | ₹504.00 | ₹3,548 Cr | 14.1 | — |

## Questions and answers

### What is the share price of Gufic Biosciences today?

Gufic Biosciences (NSE: GUFICBIO) last closed at ₹381.90 on 21 Oct 2026. Its 52-week high is ₹467.80 and its 52-week low is ₹268.00.

### What is the market cap of Gufic Biosciences?

Gufic Biosciences' market capitalisation is ₹4,051 Cr (₹4,051 Cr) at the 19 Oct 2026 close, ranking 875th among the NSE companies Pivot tracks.

### What is the P/E ratio of Gufic Biosciences?

Gufic Biosciences trades at a trailing P/E of 63.1. The median P/E of the 6 closest Pharma & Healthcare peers by market cap is 38.8.

### What is the ROE and ROCE of Gufic Biosciences?

Return on equity was 11.6% in FY25 and return on capital employed was 15.2% in FY25 (consolidated figures).

### Is Gufic Biosciences a debt-free company?

No. Gufic Biosciences' debt-to-equity ratio was 0.52 in FY25, with total debt of ₹131 Cr.

### What were Gufic Biosciences' latest quarterly results?

For Q4 FY26 (quarter ended 31 Mar 2026), Gufic Biosciences reported revenue of ₹252 Cr, +22.8% year on year, and net profit of ₹22 Cr, +183.7% year on year.

### How has Gufic Biosciences stock performed over the last year?

Gufic Biosciences' share price has risen 10.7% over the past year, +3.0% over three months and −4.9% over one month, to the 19 Oct 2026 close.

### What is the shareholding pattern of Gufic Biosciences?

As of 30 Jun 2026: promoters 72.50%, foreign institutions 0.46%, domestic institutions 3.68%, non-institutions 23.36%.

### Who are Gufic Biosciences' competitors?

The listed Pharma & Healthcare companies closest to Gufic Biosciences by market cap are Jeena Sikho Lifecare, Orchid Pharma, SMS Pharmaceuticals, Gujarat Themis Biosyn, Aarti Drugs and Unichem Laboratories.

### Is Gufic Biosciences a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Gufic Biosciences' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on GUFICBIO against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.